A Randomized, Double-Blind, Parallel-Group, Study to Evaluate the Efficacy, Safety and PK/PD of Ocrelizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy.

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Study to Evaluate the Efficacy, Safety and PK/PD of Ocrelizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 May 2016

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 01 Aug 2012 Planned End Date changed from 1 Feb 2010 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 15 Jan 2012 Results published in The Journal of Rheumatology.
    • 19 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top